Researchers at LSTM and Imperial College London have designed drugs which could help combat any potential new flu pandemic, by targeting the receptors of the cells by which the virus gains entry to the human body.
In a paper published today(link is external) in the Journal of Immunology the team, led by LSTM’s Professor Richard Pleass, show that by engineering a part of an antibody they can target the viral proteins that allow flu to mutate and become so deadly to humans.
Last year marked the centenary of the 1918 influenza pandemic that claimed nearly 100 million lives worldwide, thus becoming the deadliest disease outbreak in recorded history. Global annual influenza outbreaks account for 300,000-650,000 respiratory deaths, mostly in children and the elderly.
Professor Pleass explained: “Influenza vaccines have limited public health impact during pandemics, and current influenza vaccines are less efficacious than vaccines for many other infectious diseases. This is because influenza viruses that circulate in human and animal populations mutate two key viral surface proteins, haemagglutinin (HA) and neuraminidase (NA), thus allowing them to escape from protective antibodies produced through natural infection or vaccination”
Both HA and NA target a sugar called sialic acid, that is found in abundance on the receptors of cells lining the mammalian respiratory tract, which the virus uses to gain entry into the body. The sialic acid-binding contacts on HA and NA do not mutate readily, otherwise the virus would not be able to infect human cells.
The team has engineered antibody Fc fragments with enhanced sialic acid that target these conserved parts of both HA and NA, binding influenza viruses and thus blocking their interactions with human cells.
By targeting sialic acid, these engineered biologicals may also be useful in the control of other pathogens, such as group B streptococci, Streptococcus pneumoniae, Mycoplasma genitalium, and Newcastle Disease Virus.
“Better anti-influenza therapeutics are urgently needed.” Continued Professor Pleass: “The transfer of antibodies from people recovering from influenza during the 1918 and 2009 pandemics reduced mortality from influenza by 50% and 26% respectively. However, to be useful, these antibody medicines (also called FLU-IVIG) need to be manufactured in advance of future epidemics, which is obviously problematic as there may be modest or little neutralising activity against newly emerging strains. Therefore, combinations of existing medicines, including FLU-IVIG, with sialic acid blockers could increase their efficacy while future-proofing against the next pandemic.”
Professor Sara Marshall, Head of Clinical and Physiological Sciences at the Wellcome Trust, who provided funding for this work, said: “This is a fascinating project, and one which could have really far-reaching impact not only for influenza but as a platform technology to develop new medicines for many other diseases that are currently treated by antibodies.”
The technology described is available for licensing.
The Latest on: Anti-influenza drugs
via Google News
The Latest on: Anti-influenza drugs
- The pill that shortens the misery of fluon January 16, 2021 at 4:00 pm
Made by Roche, Tamiflu is the first oral anti-influenza medication available for adults and children aged one year and older. Like the inhaled medication Relenza, it belongs to a range of drugs ...
- The 2021-2023 Pandemic Plan is ready: "With scarcity of resources, choose who to treat first"on January 11, 2021 at 11:31 am
The draft of the new National Pandemic Plan 2021-2023 is ready, which foresees organizational measures and actions to face any new pandemics, which also draws lessons from what is happening with ...
- Industry-academia collaboration to fight flu and emerging infectionson January 6, 2021 at 6:46 pm
This article is an excerpt from the research magazine "Tackling Global Issues vol.3 Fighting the menace of zoonosis." Click here to see the table ...
- There's No Specific Drug That Kills Coronavirus. But Doctors Have Ways To Treat Iton January 3, 2021 at 9:00 pm
It can prevent the virus from doing a lot of damage at that point. The drugs can also reduce the risk of death in hospitalized patients, Aoki says. "In those cases, anti-influenza drugs will have an ...
- Fujifilm has title of Japan's top medical device maker in focuson January 2, 2021 at 9:24 pm
The anti-influenza drug Avigan from Fujifilm Toyama Chemical was hailed as a potential treatment for COVID-19, but is still awaiting government approval. Preparing for a production increase ...
- Recommendations for the Prevention and Treatment of Influenza Using Antiviral Drugs Based on Cost–Effectivenesson January 1, 2021 at 4:00 pm
Although influenza vaccination is the primary method for disease prevention, anti-influenza drugs can be used as an adjunct to vaccination as they can reduce the duration and potential ...
- DSNKYon December 27, 2020 at 4:00 pm
The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate ... and laninamivir for anti-influenza treatment. It also provides olmesartan, an ...
- Senators say drug manufacturer working to increase production in event of bird flu pandemicon December 22, 2020 at 4:00 pm
Treating about a quarter of the U.S. population would require about 73 million doses.Roche said Thursday it was halting wholesale deliveries of its anti-influenza drug Tamiflu in Germany because of ...
- Fujifilm's Avigan hopes hit after Japan puts COVID drug on holdon December 22, 2020 at 7:06 am
A health ministry official told reporters that one topic of debate at the meeting was the fact that Fujifilm's test was "single blind," meaning doctors knew which patients were receiving the drug ...
- Japan govt board: data on efficacy of COVID-19 drug candidate Avigan is inconclusiveon December 21, 2020 at 6:46 am
TOKYO (Reuters) - The Japanese Health Ministry said on Monday its medical review board concluded that clinical trial data to determine the efficacy of Fujifilm Holdings Corp’s COVID-19 drug ...
via Bing News